| MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer M Garofalo, C Quintavalle, G Di Leva, C Zanca, G Romano, C Taccioli, ... Oncogene 27 (27), 3845-3855, 2008 | 404 | 2008 |
| Cancer-associated protein kinase C mutations reveal kinase’s role as tumor suppressor CE Antal, AM Hudson, E Kang, C Zanca, C Wirth, NL Stephenson, ... Cell 160 (3), 489-502, 2015 | 347 | 2015 |
| An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers GR Villa, JJ Hulce, C Zanca, J Bi, S Ikegami, GL Cahill, Y Gu, KM Lum, ... Cancer cell 30 (5), 683-693, 2016 | 274 | 2016 |
| Contrast agents and renal cell apoptosis G Romano, C Briguori, C Quintavalle, C Zanca, NV Rivera, A Colombo, ... European heart journal 29 (20), 2569-2576, 2008 | 268 | 2008 |
| miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ C Quintavalle, M Garofalo, C Zanca, G Romano, M Iaboni, ... Oncogene 31 (7), 858-868, 2012 | 222 | 2012 |
| MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non–small-cell lung cancer through BIM down-regulation G Romano, M Acunzo, M Garofalo, G Di Leva, L Cascione, C Zanca, ... Proceedings of the National Academy of Sciences 109 (41), 16570-16575, 2012 | 195 | 2012 |
| EGFR mutation promotes glioblastoma through epigenome and transcription factor network remodeling F Liu, GC Hon, GR Villa, KM Turner, S Ikegami, H Yang, Z Ye, B Li, ... Molecular cell 60 (2), 307-318, 2015 | 191 | 2015 |
| NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling S Chowdhry, C Zanca, U Rajkumar, T Koga, Y Diao, R Raviram, F Liu, ... Nature 569 (7757), 570-575, 2019 | 182 | 2019 |
| MiR-212 increases tumor necrosis factor–related apoptosis-inducing ligand sensitivity in non–small cell lung cancer by targeting the antiapoptotic protein PED M Incoronato, M Garofalo, L Urso, G Romano, C Quintavalle, C Zanca, ... Cancer research 70 (9), 3638-3646, 2010 | 175 | 2010 |
| Epidermal growth factor receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development ZA Binder, AH Thorne, S Bakas, EP Wileyto, M Bilello, H Akbari, ... Cancer cell 34 (1), 163-177. e7, 2018 | 160 | 2018 |
| Oncogene amplification in growth factor signaling pathways renders cancers dependent on membrane lipid remodeling J Bi, TA Ichu, C Zanca, H Yang, W Zhang, Y Gu, S Chowdhry, A Reed, ... Cell metabolism 30 (3), 525-538. e8, 2019 | 148 | 2019 |
| Epidermal growth factor receptor targeting and challenges in glioblastoma AH Thorne, C Zanca, F Furnari Neuro-oncology 18 (7), 914-918, 2016 | 133 | 2016 |
| A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments K Masui, B Gini, J Wykosky, C Zanca, PS Mischel, FB Furnari, ... Carcinogenesis 34 (4), 725-738, 2013 | 132 | 2013 |
| PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3. 3 JA Benitez, J Ma, M D’Antonio, A Boyer, MF Camargo, C Zanca, S Kelly, ... Nature communications 8 (1), 15223, 2017 | 130 | 2017 |
| Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair J Ma, JA Benitez, J Li, S Miki, CP de Albuquerque, T Galatro, L Orellana, ... Cancer cell 35 (3), 504-518. e7, 2019 | 129 | 2019 |
| Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity GG Gomez, S Volinia, CM Croce, C Zanca, M Li, R Emnett, DH Gutmann, ... Cancer research 74 (5), 1429-1439, 2014 | 74 | 2014 |
| PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies A Iwanami, B Gini, C Zanca, T Matsutani, A Assuncao, A Nael, J Dang, ... Proceedings of the National Academy of Sciences 110 (11), 4339-4344, 2013 | 73 | 2013 |
| PED mediates AKT-dependent chemoresistance in human breast cancer cells G Stassi, M Garofalo, M Zerilli, L Ricci-Vitiani, C Zanca, M Todaro, ... Cancer research 65 (15), 6668-6675, 2005 | 72 | 2005 |
| Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks GG Gomez, J Wykosky, C Zanca, FB Furnari, WK Cavenee Cancer biology & medicine 10 (4), 192, 2013 | 70 | 2013 |
| Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity C Zanca, GR Villa, JA Benitez, AH Thorne, T Koga, M D'Antonio, ... Genes & development 31 (12), 1212-1227, 2017 | 65 | 2017 |
Frank FurnariUC San Diego, Dept of MedicineVerified email at ucsd.edu
